quinidine has been researched along with cifenline in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (30.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Esterbrooks, DJ; Hansen, JM; Hilleman, DE; Mohiuddin, SM; Mooss, AN; Woodruff, MP | 1 |
| Hasegawa, J; Hirokane, Y; Kotake, H; Mashiba, H; Nawada, T; Noguchi, N | 1 |
| Somberg, J | 1 |
| Flowers, NC; Maldonado, C; Palakurthy, PR; Sohi, G | 1 |
| Barr, MJ; Saksena, S; Wasty, N | 1 |
| Aogaichi, K; Butler, B; Keren, G; Miura, D; Somberg, J; Tepper, D | 1 |
| Lüderitz, B; Manz, M | 1 |
| Brembilla-Perrot, B; Gabriel, A; Lardoux, H; Levy, S; Marchand, X; Scheck, F; Touboul, P | 1 |
| Beurrier, D; Brembilla-Perrot, B; Danchin, N; Houplon, P; Jacquemin, L; Louis, P; Terrier de la Chaise, A | 1 |
| Adamantidis, M; Cardinal, R; Delfaut, P; Dupuis, B; Kacet, S; Klug, D; Lacroix, D | 1 |
| Allessie, MA; Dorland, R; Wijffels, MC | 1 |
| Allessie, MA; Dorland, R; Mast, F; Wijffels, MC | 1 |
| Kagayama, A; Mitani, Y; Niwa, T; Shiraga, T; Terakawa, M; Tokuma, Y | 1 |
2 review(s) available for quinidine and cifenline
| Article | Year |
|---|---|
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Disopyramide; Drug Administration Schedule; Encainide; Flecainide; Heart Conduction System; Humans; Imidazoles; Lidocaine; Mexiletine; Moricizine; Myocardial Contraction; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tocainide; Verapamil | 1985 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Flecainide; Humans; Imidazoles; Pre-Excitation Syndromes; Propafenone; Quinidine; Sotalol; Tachycardia, Paroxysmal; Tachycardia, Supraventricular; Verapamil | 1993 |
3 trial(s) available for quinidine and cifenline
| Article | Year |
|---|---|
Crossover comparison of cibenzoline and quinidine in ambulatory patients with chronic ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Female; Follow-Up Studies; Heart Ventricles; Humans; Imidazoles; Male; Middle Aged; Quinidine; Random Allocation | 1989 |
Comparative efficacy and safety of oral cibenzoline and quinidine in ventricular arrhythmias: a randomized crossover study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Imidazoles; Male; Middle Aged; Quinidine; Research Design | 1985 |
[Comparative effects of cibenzoline and hydroquinidine in the prevention of auricular fibrillation. A randomized double-blind study].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Quinidine; Recurrence | 1995 |
15 other study(ies) available for quinidine and cifenline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Transient increase in the contractile force induced by antiarrhythmic drugs in guinea pig cardiac muscles.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Disopyramide; Guinea Pigs; Imidazoles; In Vitro Techniques; Myocardial Contraction; Quinidine | 1989 |
Cibenzoline for high-frequency ventricular arrhythmias: a short-term comparison with quinidine and a long-term follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Quinidine | 1987 |
The efficacy of cibenzoline in preventing PES induction of ventricular tachycardia in the dog.
Topics: Animals; Anti-Arrhythmia Agents; Dogs; Electric Stimulation; Electrophysiology; Heart Rate; Imidazoles; Injections, Intravenous; Quinidine; Tachycardia | 1984 |
[Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics?].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Electrocardiography; Female; Flecainide; Heart Conduction System; Humans; Imidazoles; Male; Middle Aged; Predictive Value of Tests; Propafenone; Quinidine; Risk Factors | 1997 |
Differential effects of quinidine, flecainide, and cibenzoline on anisotropic conduction in the isolated porcine heart.
Topics: Action Potentials; Animals; Anisotropy; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac Pacing, Artificial; Female; Flecainide; Heart; Heart Conduction System; Imidazoles; In Vitro Techniques; Pericardium; Potassium Channel Blockers; Quinidine; Swine | 1998 |
Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Disease Models, Animal; Electrocardiography; Flecainide; Follow-Up Studies; Goats; Heart Conduction System; Imidazoles; Injections, Intravenous; Quinidine; Secondary Prevention; Sotalol; Treatment Outcome | 1999 |
Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Goats; Heart Conduction System; Imidazoles; Quinidine; Sotalol | 2000 |
Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Topics: Animals; Anti-Arrhythmia Agents; Aryl Hydrocarbon Hydroxylases; beta-Naphthoflavone; Cell Line; Chromatography, High Pressure Liquid; Clofibrate; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Female; Humans; Imidazoles; Ketoconazole; Kinetics; Male; Microsomes; Microsomes, Liver; Oxidoreductases, N-Demethylating; Phenobarbital; Quinidine; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sex Factors; Stereoisomerism | 2000 |